At the end of next month, the European Medicines Agency (EMEA) will implement a new legislative framework and several provisions that seek to provide incentives and streamline regulatory oversight of certain monoclonal antibodies and other biologic products.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
The European Parliament and the Council of the European Union. Off. J. Eur. Union. L136/2, 34–57 (2004).
The European Parliament and the Council of the European Union. Off. J. Eur. Union. L136/2, 1–33 (2004)
The Commission of the European Communities. Off. J. Eur. Union. L15, 17–38 (1987).
The Commission of the European Communities. Off. J. Eur. Union. L159, 46–94 (2003).
Taste, J.-B. Nat. Biotechnol. 22, 1490 (2004).
European Commission. Provisions for Micro, Small and Medium-Sized Enterprises (SMEs), Establishing the Circumstances in Which SMEs May Pay Reduced Fees, Defer Payment of the Fee, or Receive Administrative Assistance. (EC, Brussels, Belgium, October 2004). http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2004/nov/SMEs%20provisions-Consultation%20paper-10142004.pdf
European Medicines Agency. EMEA Public Statement on Fee Reductions for Designated Orphan Medicinal Products of 7 January 2005 (EMEA-H-4042-01.Rev.5) (EMEA, London, UK, January 7, 2005). http://www.emea.eu.int/pdfs/human/comp/404201en.pdf
The European Agency for the Evaluation of Medicinal Products. PIM System Specifications. Ref: EMEA/19503/04/v1/6/en/Final (EMEA, London, 2004) http://pim.emea.eu.int/doc/PIM%20Specifications%20-%20Business%20Case%20v1-6-en.pdf
European Commission. Draft Commission Regulation on the Conditional Marketing Authorisation for Medicinal Products Falling Within the Scope of Regulation (EC) No 726/2004 of the European Parliament and the Council of 31 March 2004. (EC, Brussels, Belgium, November 9, 2004). http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2004/nov/draft-regulation_13-10-2005.pdf
European Medicines Agency. Accelerated Evaluation of Products Indicated for Serious Diseases (Life-Threatening or Heavily Disabling Diseases) (CPMP/495/96 rev.1) (EMEA, London, UK, September 18, 2001). http://www.emea.eu.int/pdfs/human/regaffair/049596en.pdf
Sheridan, C. Nat. Biotechnol. 23, 397–398 (2005).
European Commission. The Rules Governing Medicinal Products in the European Union: Pharmacovigilance for Medicinal Products for Human and Veterinary Use, vol. 9 (EC, Brussels, 2004).
Acknowledgements
I would like to thank Donald Beers for help in the preparation of this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsang, L. Overhauling oversight—European drug legislation. Nat Biotechnol 23, 1050–1053 (2005). https://doi.org/10.1038/nbt0905-1050
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1050